Exploring Psychedelics as the Next Wave of Psychiatric Innovation

On this episode of Advances in Care, Erin Welsh revisits her conversations with Dr. Richard Friedman, a clinical psychiatrist at NewYork-Presbyterian and director of the Psychopharmacology Clinic at Weill Cornell Medicine, and Dr. David Hellerstein, a research psychiatrist at NewYork-Presbyterian and Columbia, about the challenges of conventional therapeutics like SSNRIs and SSRIs and how psychedelic compounds could provide different treatment mechanisms. They discuss the challenges of testing clinically testing psychedelics, and how different psychedelics could be an avenue of treatment for a range of mental health disorders.